Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference 

Crinetics Pharmaceuticals ($CRNX) will provide a company update at the 40th annual J.P. Morgan Healthcare Conference today, Wednesday, January 12th at 4:30 PM Eastern Time.

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

Crinetics Pharmaceuticals ($CRNX) announced today that Rogério Vivaldi Coelho, M.D., M.B.A., an expert in rare and orphan diseases, has joined the company's board of directors.

Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Crinetics Pharmaceuticals ($CRNX) announced today that company management will participate in a fireside chat and one-on-one investor meetings at the Annual Evercore ISI HealthCONx Conference.

Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

Crinetics Pharmaceuticals ($CRNX) announced today that new data from ACROBAT Advance, the ongoing open label extension (OLE) trial of paltusotine in patients with acromegaly, will be featured in a poster presentation at the annual Society for Endocrinology BES congress in Edinburgh, Scotland.

Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

We also continue to make strong progress in our efforts to develop paltusotine as an oral treatment for acromegaly and neuroendocrine tumors complicated by carcinoid syndrome. With a strong financial foundation that was recently bolstered by our successful common stock offering, we believe we are well positioned to advance our pipeline programs and achieve a regular cadence of milestones.